EMA Authorised: Kyinsu (insulin icodec;semaglutide) — Novo Nordisk A/S

View source ↗

Summary

The EMA authorised Kyinsu, a fixed-dose combination of insulin icodec and semaglutide, for type 2 diabetes mellitus, with Novo Nordisk A/S as the marketing auth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Kyinsu (insulin icodec; semaglutide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novo Nordisk A/S. Decision date: 24/11/2025